FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839690, encodeId=106b1839690d6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了ABO-202基因疗法治疗CLN1的研究性新药申请, objectType=article, longId=166647, objectId=a9b216664e69, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9b216664e69, replyNumber=0, likeNumber=67, createdTime=2019-08-01, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9b216664e69, moduleTitle=FDA批准了ABO-202基因疗法治疗CLN1的研究性新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9b216664e69)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839697, encodeId=50c2183969e9d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Novo Nordisk的Victoza治疗2型糖尿病儿童患者, objectType=article, longId=168713, objectId=ec97168e1391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec97168e1391, replyNumber=0, likeNumber=56, createdTime=2020-02-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec97168e1391, moduleTitle=FDA批准Novo Nordisk的Victoza治疗2型糖尿病儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec97168e1391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=强生的Spravato获FDA批准用于治疗抵抗性抑郁症, objectType=article, longId=161783, objectId=f906161e83cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f906161e83cd, replyNumber=0, likeNumber=71, createdTime=2019-08-05, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f906161e83cd, moduleTitle=强生的Spravato获FDA批准用于治疗抵抗性抑郁症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f906161e83cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839696, encodeId=e77b1839696e8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Emflaza治疗年轻DMD患者, objectType=article, longId=168071, objectId=6ea81680e175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ea81680e175, replyNumber=0, likeNumber=97, createdTime=2019-10-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ea81680e175, moduleTitle=FDA批准Emflaza治疗年轻DMD患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ea81680e175)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839672, encodeId=892418396e2b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Merck的Mavenclad（克拉屈滨）用于治疗多发性硬化症, objectType=article, longId=163429, objectId=01811634295d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01811634295d, replyNumber=0, likeNumber=59, createdTime=2019-12-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01811634295d, moduleTitle=FDA批准Merck的Mavenclad（克拉屈滨）用于治疗多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01811634295d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839681, encodeId=84d51839681a9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Qternmet XR治疗2型糖尿病, objectType=article, longId=165389, objectId=e4fd16538992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4fd16538992, replyNumber=0, likeNumber=57, createdTime=2019-06-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4fd16538992, moduleTitle=FDA批准Qternmet XR治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4fd16538992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839628, encodeId=2e60183962804, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准新型抗菌药物治疗严重肺病, objectType=article, longId=149989, objectId=a8e514998999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8e514998999, replyNumber=0, likeNumber=81, createdTime=2019-04-04, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8e514998999, moduleTitle=美国FDA批准新型抗菌药物治疗严重肺病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8e514998999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839644, encodeId=286d18396440c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=谷歌Verily智能手表获美国FDA批准，可用于心电图节律检测, objectType=article, longId=158660, objectId=529c158660c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=529c158660c2, replyNumber=0, likeNumber=72, createdTime=2019-04-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=529c158660c2, moduleTitle=谷歌Verily智能手表获美国FDA批准，可用于心电图节律检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=529c158660c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839646, encodeId=d9b81839646ff, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准MGB Biopharma的新型抗生素IND申请治疗艰难梭菌相关性腹泻, objectType=article, longId=158875, objectId=0f461588e508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f461588e508, replyNumber=0, likeNumber=81, createdTime=2019-08-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f461588e508, moduleTitle=FDA批准MGB Biopharma的新型抗生素IND申请治疗艰难梭菌相关性腹泻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f461588e508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839699, encodeId=417218396991b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉, objectType=article, longId=174393, objectId=fc561e4393b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc561e4393b5, replyNumber=0, likeNumber=91, createdTime=2020-05-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc561e4393b5, moduleTitle=FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc561e4393b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839693, encodeId=d0a61839693c9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎, objectType=article, longId=167634, objectId=b63116e634f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b63116e634f3, replyNumber=0, likeNumber=58, createdTime=2019-06-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b63116e634f3, moduleTitle=Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b63116e634f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839638, encodeId=b5fa18396385b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=HighTide制药的非酒精性脂肪性肝炎（NASH）疗法HTD1801已获得美国FDA批准, objectType=article, longId=154608, objectId=aa811546081e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa811546081e, replyNumber=0, likeNumber=60, createdTime=2019-08-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa811546081e, moduleTitle=HighTide制药的非酒精性脂肪性肝炎（NASH）疗法HTD1801已获得美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa811546081e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839668, encodeId=560718396689a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了优先审查赛诺菲的白细胞介素-4单抗Dupixent治疗鼻窦炎, objectType=article, longId=161943, objectId=954e161943f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=954e161943f4, replyNumber=0, likeNumber=50, createdTime=2020-02-15, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=954e161943f4, moduleTitle=FDA批准了优先审查赛诺菲的白细胞介素-4单抗Dupixent治疗鼻窦炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=954e161943f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839633, encodeId=d21418396338c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准艾尔建sarecycline治疗9岁以上中重度痤疮, objectType=article, longId=150494, objectId=5c1e150494bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c1e150494bc, replyNumber=0, likeNumber=71, createdTime=2018-11-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c1e150494bc, moduleTitle=FDA批准艾尔建sarecycline治疗9岁以上中重度痤疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c1e150494bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839685, encodeId=751e1839685f8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, objectType=article, longId=166173, objectId=9b091661e313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b091661e313, replyNumber=0, likeNumber=66, createdTime=2020-01-04, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b091661e313, moduleTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b091661e313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839682, encodeId=39ca1839682d1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Vyndaqel及Vyndamax获得FDA批准用于成人心肌病, objectType=article, longId=165568, objectId=61461655680f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61461655680f, replyNumber=0, likeNumber=59, createdTime=2020-02-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61461655680f, moduleTitle=Vyndaqel及Vyndamax获得FDA批准用于成人心肌病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61461655680f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839700, encodeId=99831839e0084, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准daratumumab联合来那度胺和地塞米松治疗初治多发性骨髓瘤, objectType=article, longId=174421, objectId=3d441e442153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d441e442153, replyNumber=0, likeNumber=75, createdTime=2019-11-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d441e442153, moduleTitle=美国FDA批准daratumumab联合来那度胺和地塞米松治疗初治多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d441e442153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839680, encodeId=95f4183968026, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=纳洛酮鼻腔喷雾剂仿制药获FDA批准，用于治疗阿片类药物服用过量, objectType=article, longId=164872, objectId=56031648e274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56031648e274, replyNumber=0, likeNumber=48, createdTime=2019-11-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56031648e274, moduleTitle=纳洛酮鼻腔喷雾剂仿制药获FDA批准，用于治疗阿片类药物服用过量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56031648e274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839616, encodeId=c981183961628, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Vertex公司的Kalydeco药物用于治疗两岁以下的囊性纤维化儿童患者, objectType=article, longId=146819, objectId=0a1e14681910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a1e14681910, replyNumber=0, likeNumber=69, createdTime=2018-11-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a1e14681910, moduleTitle=FDA批准Vertex公司的Kalydeco药物用于治疗两岁以下的囊性纤维化儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a1e14681910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839654, encodeId=63731839654a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=纳米抗体药Cablivi获FDA批准治疗罕见凝血障碍, objectType=article, longId=160608, objectId=68541606084c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68541606084c, replyNumber=0, likeNumber=84, createdTime=2019-10-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68541606084c, moduleTitle=纳米抗体药Cablivi获FDA批准治疗罕见凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68541606084c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了ABO-202基因疗法治疗CLN1的研究性新药申请

2019-08-01

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Novo Nordisk的Victoza治疗2型糖尿病儿童患者

2020-02-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

强生的Spravato获FDA批准用于治疗抵抗性抑郁症

2019-08-05

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Emflaza治疗年轻DMD患者

2019-10-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Merck的Mavenclad（克拉屈滨）用于治疗多发性硬化症

2019-12-29

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Qternmet XR治疗2型糖尿病

2019-06-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准新型抗菌药物治疗严重肺病

2019-04-04

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

谷歌Verily智能手表获美国FDA批准，可用于心电图节律检测

2019-04-16

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准MGB Biopharma的新型抗生素IND申请治疗艰难梭菌相关性腹泻

2019-08-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉

2020-05-22

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎

2019-06-18

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

HighTide制药的非酒精性脂肪性肝炎（NASH）疗法HTD1801已获得美国FDA批准

2019-08-10

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了优先审查赛诺菲的白细胞介素-4单抗Dupixent治疗鼻窦炎

2020-02-15

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准艾尔建sarecycline治疗9岁以上中重度痤疮

2018-11-21

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌

2020-01-04

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Vyndaqel及Vyndamax获得FDA批准用于成人心肌病

2020-02-06

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准daratumumab联合来那度胺和地塞米松治疗初治多发性骨髓瘤

2019-11-26

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

纳洛酮鼻腔喷雾剂仿制药获FDA批准，用于治疗阿片类药物服用过量

2019-11-12

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Vertex公司的Kalydeco药物用于治疗两岁以下的囊性纤维化儿童患者

2018-11-26

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

纳米抗体药Cablivi获FDA批准治疗罕见凝血障碍

2019-10-24

科室
- - 订阅+
  - 更多科室
工具
服务